Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07527650) titled 'Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus' on April 7.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).
Primary Sponsor: Hanmi Pharmaceutical Company Limited
Condition:
Type 2 Diabetes Mellitus
T2DM
Intervention:
Drug: HM15275
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: May 2026
Target Sample Size: 180
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT...